Onconetix 11/17/2023 Earnings Report $0.07 0.00 (-5.97%) As of 04/8/2025 04:00 PM Eastern Earnings History Onconetix EPS ResultsActual EPS-$11.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOnconetix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOnconetix Announcement DetailsQuarterDate11/17/2023TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsOnconetix's next earnings date is estimated for Thursday, April 10, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryONCO Profile Remove Ads Onconetix Earnings HeadlinesOnconetix signs non-binding LOI for potential combination with OcuvexApril 9 at 2:15 AM | markets.businessinsider.comCincinnati's Onconetix pursuing merger deal with drug development firmApril 8 at 3:36 PM | bizjournals.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 9, 2025 | Paradigm Press (Ad)Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.April 8 at 10:35 AM | markets.businessinsider.com🌱 Cincinnati's arena debate heats upApril 6 at 6:16 AM | msn.comOnconetix executive chairman resigns in latest leadership exit; interim CFO named new top leaderApril 5, 2025 | bizjournals.comSee More Onconetix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Onconetix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Onconetix and other key companies, straight to your email. Email Address About OnconetixOnconetix (NASDAQ:ONCO), a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.View Onconetix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
